Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC.
NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: February 08, 2022
Curative-Intent Treatment with Durvalumab in Early-Stage Cancers.
Journal: Advances in therapy
Published: January 22, 2021
A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: September 24, 2020
Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial.
Journal: JAMA oncology
Published: April 10, 2020
Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial.
Journal: JAMA oncology
Published: January 25, 2019
Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial.
Journal: Journal for immunotherapy of cancer
Published: October 24, 2018
Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial.
Journal: Journal for immunotherapy of cancer
Published: April 30, 2018
Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives.
Journal: Cancer treatment reviews
Published: January 29, 2018
Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: March 01, 2017
Avelumab: clinical trial innovation and collaboration to advance anti-PD-L1 immunotherapy.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: January 25, 2017
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: September 09, 2015
Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial.
Journal: The Lancet. Oncology
Published: April 23, 2015
Last Updated: 09/26/2026